Hold core position; trim 25-50% into strength toward $445+; do not add until either a confirmed basing pattern above the 10-day EMA with MACD histogram turning positive, or a flush to $387-$400 zone where the 50-day SMA provides structural support and forward P/E drops to ~16x.

• Q2 diluted EPS was $4.37 (annualized = $17.48, vs. street estimate of $24.40)
• Forward P/E of 17.96x represents thin margin of safety at current price
• Stock sits 24.5% above rising 200-day moving average; fresh MACD bearish cross printed
• First support at 10-day EMA ($432.94); next support is 50-day SMA ~$50 away (~11% decline)
• 50-day SMA and 200-day SMA backstops lie in the $387-$400 zone with forward P/E ~16x
• Potential downside if topping pattern resolves: 15-25% to 200-day SMA or below
• Total debt of $57.3 billion; 2.5x net debt to EBITDA; negative tangible book value of $27.47 billion
• ROE of 91% mechanically inflated by share buybacks shrinking equity base
• Beta of 0.413 reflects historical volatility but not sensitivity to multiple compression
• IRA and Medicare pricing pressure flagged by Trefis lowers structural multiple ceiling
• Aggressive analyst's add levels: $440.62 and $454.66 rejected as buying into resistance with deteriorating momentum
• Prediction markets show Fed cut expectations being revised lower week-over-week, tightening financial conditions
• Repatha's 20% mortality reduction did not move the stock; market already reflected commercial trajectory

→ vs aggressive: Forward EPS of $24.40 requires ~$1.75B of incremental quarterly net income with no clear Q3 2026 catalyst; Repatha mortality data and Tezspire EoE are 2027+ stories

→ vs aggressive: Technical setup represents late-stage momentum pattern; distribution of outcomes from $438 is worse than from $400 due to thin 10-day EMA support vs. 50/200-day SMA backstops

→ vs aggressive: Clinical data being eventually rewarded requires believing the market mispriced a major clinical event; historically a low-conviction trade given Repatha data produced no stock response

→ vs aggressive: Adding above $440.62 or $454.66 at all-time highs with MACD bearish cross, sector de-rating, and Fed uncertainty is buying into resistance with deteriorating momentum

→ vs aggressive: Leverage amplifies equity downside relative to less-levered peers if Fed stays restrictive and biotech multiples compress 10-15%; ROE of 91% is mechanically inflated by buybacks, not operational strength

→ vs aggressive: Hawkish Fed not fully priced in; prediction market data shows cut expectations actively revised lower week-over-week, tightening financial conditions that have not fully expressed in biotech multiples

→ vs neutral: Technical picture is stronger than neutral analyst credited; first support at $432.94 is thin, but the $387-$400 zone with 50-day SMA and ~16x forward P/E is a defensible entry if reached

HOLD at 3-4% weight; add 1.5x weight only in $387-$400 zone on MACD confirmation or $420-$432 on stabilization; rule out adding above $440; treat $387.94 stop as structural invalidation

• First add zone is $420-$432 where Bollinger middle and 10 EMA converge, on confirmed stabilization only
• Full 1.5x weight upgrade zone at $387-$400 aligns with 50-day SMA, 16-16.5x forward P/E, and MACD reset completion
• $24.40 consensus EPS may not be conservative enough to anchor a buy at current prices
• 20-22x multiple scenario ($488-$537) requires multiple expansion that current tape is actively denying given sentiment score of 6.2 vs 9.0
• 2.5x net debt/EBITDA and negative tangible book are structural to biotech industry post-Horizon, not unique risk flags
• Underlying profitability is genuine: 22.95% net margin, 35% operating margin, 91% ROE (buyback-influenced)
• Repatha 20% mortality reduction and Tezspire in EoE (470,000-patient pool) are multi-year value drivers not captured in short-term tape
• Adding above $440 constitutes chasing given fresh MACD bearish cross and negative divergence at all-time highs
• Stop at $387.94 is structural invalidation level triggering full de-risking regardless of catalyst narrative

→ vs aggressive: Forward EPS path of $24.40 is labeled but not explained; Q2 35% operating margin driven by discrete mix and cost discipline that may not linearly extrapolate

→ vs aggressive: Back-of-envelope $488-$537 scenario at 20-22x multiple requires multiple expansion actively denied by 6.2 sentiment score

→ vs aggressive: Confirmation at all-time highs after 64% advance is lower quality signal than confirmation at bottom of basing pattern

→ vs aggressive: Trend integrity is poor timing tool when entry is already at upper extreme of range; August 2021 precedent showed 30%+ drawdown from similar setup

→ vs conservative: Trim suggestion is emotional reaction to all-time highs rather than disciplined risk response; balance sheet is not binding constraint with 8x interest coverage and 1.6x FCF dividend coverage

→ vs conservative: Net debt declined by nearly $5B in a year; negative tangible book is structural to industry post-large acquisitions, not AMGN-specific flag

→ vs conservative: Barron's biotech slide observation is sector flow, not refutation of AMGN-specific catalysts with multi-year compounding value into 2027-2028

→ vs conservative: Using 'not a near-term driver' to dismiss clinical catalysts like Repatha mortality reduction and Tezspire EoE ignores multi-year label expansion and payer positioning value